| General Information of Drug Metabolite (DM) (ID: DM006030) |
| DM Name |
Trans-hydroxyperhexilline
|
| PubChem CID |
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2B6 (CYP2B6)
|
DME0020
|
| Oxidation - Aliphatic hydroxylation |
WSM-3978G
|
[1] |
|
Cytochrome P450 2D6 (CYP2D6)
|
DME0009
|
| Oxidation - Aliphatic hydroxylation |
WSM-3978G
|
[1] |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Oxidation - Aliphatic hydroxylation |
WSM-3978G
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| WSM-3978G |
DR1260
|
Phase 3 |
Hypertrophic cardiomyopathy |
|
|
| References |
| 1 |
CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
